Novo nornord recombinant coagulation factor VIII ."" (Turoctocog alfa) listed in China
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Novo Nordisk recombinant clotting factor VIII (Turoctocog alfa, trade name: Novoeight) was listed domestically for the treatment of type A haemophiliaPreviously, Zhengda Sun has completed clinical phase III ahead of Novo nor Nordisk, but Novo nor Nordisk took the first step to submit a listing application to NMPAon Turoctocog alfaTuroctocog alfa is a B-domain-borne recombinant human coagulation factor VIII, used for the prevention and treatment of bleeding events in patients with type A haemophiliaTuroctocog alfa, a(http:// product(http://) product of Novo nor Nordisk's third-generation recombinant clotting factor, was approved by theFDA(http://in October 2013, taking advantage of the latest gene recombination and protein purification technologyTuroctocog alfa was evaluated in Phase III Guardian, the largest clinicalpreenomictrial(http://program ever conducted in a type A haemophiliac patient, involving more than 200 cases of haemophilia type AThese Phase III clinical trials conducted by Novo Nordisk, which included previously treated severe type A haemophilia adults and children, demonstrated the efficacy of Turoctocog alpha in the prevention and treatment of bleeding events, while no inhibitors were produced in the patient Today, NovoNovoeight and Novoseven have annual global sales of about $2 billion
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
